Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corcept Therapeutics reports robust earnings, navigates legal challenges for growth

Corcept Therapeutics demonstrated strong financial performance, stability, and strategic investments in key areas of its business.
While facing legal challenges and adapting to industry changes, the company capitalized on opportunities for growth and innovation.
Overall, Corcept's focus on clinical advancements and strategic investments positions it well for future success and expansion in the healthcare sector.

Corcept Therapeutics reports revenue growth, legal battles with Teva

Corcept Therapeutics delivered strong Q1 performance with revenue growth and a robust financial position.
The company faces challenges in managing expenses, legal battles, and sustaining R&D investments.
Opportunities lie in sales force expansion, clinical trials, and upcoming studies for growth and innovation.
Overall, Corcept's strategic focus on growth and legal defense positions it for future success in the market.

Corcept Therapeutics reports robust Q2 earnings and expands treatment reach

Corcept Therapeutics delivered strong financial performance, raised revenue guidance, and showcased progress in clinical development programs.
While facing legal challenges and market expansion complexities, the company's proactive strategies and positive trial results position it well for future growth.
Opportunities in partnerships, physician engagement, and broadening disease applications underscore Corcept's potential for continued success and impact in the healthcare industry.

Corcept Therapeutics excels in Q3, eyes growth in new markets

Corcept Therapeutics demonstrated robust financials, strategic wins in legal battles, and a focus on market expansion and product innovation.
While facing challenges in maintaining competitive positioning and navigating regulatory landscapes, the company is poised for growth.
With a strong performance in Q3 2023 and promising opportunities ahead, Corcept is well-positioned to capitalize on its strengths and drive future success.

Corcept Therapeutics reports robust Q4 revenue and diversifies pipeline

Corcept Therapeutics demonstrated strong financial performance in Q4 2023 with revenue growth and profitability.
The company's ongoing research and diversified pipeline position it well for future growth.
Challenges include legal disputes and market competition, but strategic planning and label expansions offer opportunities.
Overall, Corcept's financial stability, confidence in growth, and focus on treatment efficacy are key takeaways.

Corcept Therapeutics reports robust Q1 performance and eyes market expansion

Corcept Therapeutics delivered strong financial performance in Q1 2024, with revenue growth, increased net income, and raised revenue guidance.
The company's focus on innovative treatments for hypercortisolism and various cancers positions it well for future growth and market expansion.
While facing challenges like legal battles and operational complexity, Corcept remains optimistic about its pipeline and market potential.

Corcept Therapeutics reports strong Q2 performance amidst pipeline advancements

Corcept Therapeutics demonstrated robust financial performance and commercial growth in Q2 2024, supported by a strong cash position.
The company's pipeline strength was evident through positive study results for relacorilant and ongoing trials in various medical conditions.
While facing legal challenges and NDA submission delays, Corcept has opportunities to leverage its pipeline and market strategies for future success.

Corcept Therapeutics reports strong Q3 earnings and advances pipeline

Corcept Therapeutics delivered robust financial results, showing substantial revenue growth and profitability in Q3 2024. The company's pipeline progress and expanded revenue guidance underscore its strong market position and growth potential.
While facing legal challenges and complexities in clinical development, Corcept's strategic initiatives in multiple therapeutic areas and combination therapies position it well to capitalize on market opportunities and drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics (CORT) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology ( ESMO21 ) Congress 2021. The trial included 178 patients with recurrent platinum-resistant ovarian cancer.

Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer

MENLO PARK, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer were featured in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer will be featured in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021. The congress will take place from September 16 – 21, 2021.

Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021

MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced the appointment, effective August 16, 2021, of William Guyer, PharmD, as the company's Chief Development Officer.

William Guyer to join Corcept as Chief Development Officer

Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.

Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2021 Results - Earnings Call Transcript

Zoetis

CORT vs. ZTS: Which Stock Is the Better Value Option?

CORT or ZTS: Which Is the Better Value Stock Right Now?

MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced that Amy Flood has joined the company as Chief Human Resources and Communications Officer.

Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

MENLO PARK, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced preliminary results from its Phase 3 RELIANT trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer.

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities ("Sun") resolving patent litigation related to Korlym®, Corcept's medication for the treatment of patients with Cushing's syndrome. The litigation has been pending in the United States District Court for the District of New Jersey since 2019, shortly after Sun notified Corcept that it had submitted an Abbreviated New Drug Application (ANDA) to the United States Food and Drug Administration (FDA) seeking approval to market a generic version of Korlym.

Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company's Board of Directors.

Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well.

Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition

Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.

Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call Transcript

MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended March 31, 2021.

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results

MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced positive results from its 178-patient, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon

Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?

Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant

MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck's medication, Keytruda®) in patients with adrenal cancer with cortisol excess.

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.

News for Corcept Therapeutics Stock (CORT)